Oneness Biotech Co., Ltd. Advances SNS851 to Phase 1 MAD

Oneness Biotech advanced its siRNA candidate SNS851 to the multiple-ascending dose part of a Phase 1 trial after completing SAD in healthy volunteers; MAD will enroll participants with fatty liver disease, with data expected in Q1 2027.Material DetailsContext by AI AnalystThis is an early-stage cli…